Item 2.02 Results of Operations and Financial Condition.

On August 12, 2022, PLx Pharma Inc. (the "Company") issued a press release announcing its financial results for its second quarter ended June 30, 2022 and other business updates. The Company's press release is attached hereto as Exhibit 99.1 and the information set forth therein is incorporated herein by reference and constitutes a part of this report.

The information furnished by the Company pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liability of that section, and shall not be deemed to be incorporated by reference into any Company filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.




 Item 8.01 Other Events.

On August 12, 2022, the Company issued a press release providing business updates, including the Company's recent engagement of a financial advisor to commence a formal process to evaluate strategic alternatives to enhance stockholder value. The Company's press release is attached hereto as Exhibit 99.1 and the information set forth therein is incorporated herein by reference and constitutes a part of this report.

Item 9.01 Financial Statements and Exhibits.





(d)  Exhibits

     Exhibit No.  Description

     99.1           Press Release, dated August 12, 2022.

     104          Cover Page Interactive Data File (the cover page XBRL tags are
                  embedded within the Inline XBRL document).

© Edgar Online, source Glimpses